Market closed
Milestone Scientific/$MLSS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Milestone Scientific
Milestone Scientific Inc is engaged in pioneering proprietary, technological systems, and solutions for the medical and dental markets. It develops, manufactures, markets, and sells the computer-controlled system for the improved and painless delivery of local anesthetic. The system is marketed in dentistry under the trademark CompuDent and in medicine under the trademark CompuMed. In addition, the company provides The Wand, a handpiece that allows dentists to provide painless injections for virtually various dental procedures, including routine cleanings and fillings, as well as implants, root canals, and crowns. The Company conducts its business through two reportable segments: Dental and Medical. Geographically all the operations of the firm function through the region of the U.S.
Ticker
$MLSS
Sector
Trading on
AMEX
Industry
Health Care Equipment & Supplies
Headquarters
Employees
17
Website
MLSS Metrics
BasicAdvanced
$68M
-
-$0.06
1.10
-
Price and volume
Market cap
$68M
Beta
1.1
52-week high
$1.39
52-week low
$0.54
Average daily volume
87K
Financial strength
Current ratio
2.847
Quick ratio
1.418
Long term debt to equity
2.709
Total debt to equity
4.316
Management effectiveness
Return on assets (TTM)
-38.46%
Return on equity (TTM)
-65.21%
Valuation
Price to revenue (TTM)
7.704
Price to book
9.36
Price to tangible book (TTM)
9.56
Price to free cash flow (TTM)
-25.668
Growth
Revenue change (TTM)
-9.49%
Earnings per share change (TTM)
-39.26%
3-year revenue growth (CAGR)
-2.81%
3-year earnings per share growth (CAGR)
-14.77%
What the Analysts think about MLSS
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Milestone Scientific stock.
MLSS Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
MLSS Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
MLSS News
AllArticlesVideos
Milestone Scientific Expands CompuFlo® Epidural System Footprint with InfiniSurg, LLC in New Jersey
GlobeNewsWire·5 days ago
Milestone Scientific Expands Adoption of CompuFlo® Epidural System with Commercial Rollout at Pain Doctors Medical LLC
GlobeNewsWire·2 months ago
Milestone Scientific Announces Commercial Rollout of CompuFlo® Epidural System at Advanced Spine and Pain Management Following Successful Pilot with Dr. Varinder Dhillon
GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Milestone Scientific stock?
Milestone Scientific (MLSS) has a market cap of $68M as of April 06, 2025.
What is the P/E ratio for Milestone Scientific stock?
The price to earnings (P/E) ratio for Milestone Scientific (MLSS) stock is 0 as of April 06, 2025.
Does Milestone Scientific stock pay dividends?
No, Milestone Scientific (MLSS) stock does not pay dividends to its shareholders as of April 06, 2025.
When is the next Milestone Scientific dividend payment date?
Milestone Scientific (MLSS) stock does not pay dividends to its shareholders.
What is the beta indicator for Milestone Scientific?
Milestone Scientific (MLSS) has a beta rating of 1.1. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.